\-\ Texto\\:\\ \ \(0\)\
\-\ pleasant\\,\\ high\\ functioning\\ elderly\\ female\\ without\\ abnormal\\ physical\\ exam\\ abnormalities\\.\ \(0\)\
\-\ pet\\/ct\\ showed\\ no\\ evidence\\ of\\ metastasis\\.\\ multiple\\ treatment\\ options\\ to\\ include\\ left\\ lower\\ lobectomy\\/wedge\\ resection\\ were\\ considered\\.\\ \\ however\\,\\ given\\ advanced\\ age\\ and\\ low\\ grade\\ adenocarcinoma\\,\\ the\\ patient\\ opted\\ for\\ definitive\\ external\\ beam\\ irradiation\\.\ \(0\)\
\-\ 1\\.2\\ x\\ 1\\.4\\ cm\\ left\\ lower\\ lobe\\ ground\\ glass\\ pulmonary\\ nodule\\ without\\ significant\\ metabolic\\ activity\\.\\ of\\ note\\,\\ chest\\ ct\\ one\\ year\\ prior\\ showed\\ correlating\\ 1\\.0\\ cm\\ pulmonary\\ nodule\\.\ \(0\)\
\-\ adenocarcinoma\\ of\\ the\\ lung\\.\ \(2\)\
\-\ infection\\/inflammation\\:\\ atypical\\ or\\ early\\ bacterial\\.\ \(0\)\
\-\ tumor\\:\\ low\\ grade\\ \\(e\\.g\\.\\,\\ bronchioloalveolar\\)\\ or\\ well\\ differentiated\\ adenocarcinoma\\;\\ mucinous\\ tumors\\ \\(e\\.g\\.\\,\\ bronchioloalveolar\\)\\;\\ carcinoid\\;\\ mucoepidermoid\\ carcinoma\\;\\ adenoid\\ cystic\\ carcinoma\\;\\ pleomorphic\\ carcinoma\\.\\ most\\ metastasis\\ and\\ lymphoma\\ are\\ unlikely\\ given\\ the\\ lack\\ of\\ significant\\ activity\\.\ \(0\)\
\-\ 86\\ year\\ old\\ female\\ with\\ history\\ of\\ esophageal\\ cancer\\ status\\ post\\ esophagectomy\\ presents\\ with\\ unexplained\\ weight\\ loss\\ \\(30\\ pounds\\ over\\ past\\ 2\\ years\\)\\.\\ \\ 18\\-fdg\\ pet\\/ct\\ performed\\.\ \(0\)\
\-\ though\\ extremely\\ valuable\\ in\\ the\\ workup\\ and\\ evaluation\\ of\\ cancer\\ patients\\,\\ among\\ several\\ factors\\ such\\ as\\ lesion\\ size\\,\\ f\\-18\\ fdg\\ pet\\ imaging\\ is\\ dependent\\ on\\ the\\ enhanced\\ glycolytic\\ rate\\ \\(aka\\ metabolic\\ activity\\)\\ of\\ malignant\\ cells\\ to\\ demonstrate\\ elevated\\ suvs\\.\\ \\ thus\\,\\ many\\ low\\ grade\\ or\\ well\\-differentiated\\ tumors\\ will\\ not\\ demonstrate\\ increased\\ fdg\\ avidity\\.\\ \\ classic\\ examples\\ include\\ bronchoalveolar\\ carcinoma\\ \\(low\\ grade\\ adenocarcinoma\\)\\ and\\ carcinoid\\.\\ \\ \ \(0\)\
\-\ at\\ times\\,\\ borderline\\ elevated\\ \\(above\\ 2\\.5\\)\\ suvs\\ can\\ be\\ seen\\ in\\ these\\ tumors\\ which\\ further\\ complicates\\ specificity\\.\\ \\ one\\ strategum\\ for\\ differentiating\\ infectious\\/inflammatory\\ pulmonary\\ lesions\\ from\\ tumor\\ is\\ dual\\-time\\ point\\ imaging\\,\\ where\\ a\\ second\\ more\\ delayed\\ pet\\ is\\ performed\\ and\\ compared\\ with\\ initial\\ imaging\\.\\ \\ classically\\,\\ infection\\/inflammation\\ suv\\ decreases\\,\\ and\\ tumor\\ suv\\ increases\\.\\ \\ alternatively\\,\\ other\\ pet\\ radiopharmaceuticals\\ can\\ be\\ used\\,\\ such\\ as\\ c11\\ acetate\\,\\ although\\ these\\ isotopes\\ are\\ still\\ largely\\ experimental\\,\\ not\\ routinely\\ available\\,\\ and\\ only\\ fdg\\ is\\ currently\\ cms\\ approved\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ pet\\:\\ 0\\.2755504525552719\ \(0\)\
\-\ fdg\\:\\ 0\\.25778553500230333\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.1945414698012642\ \(0\)\
\-\ suvs\\:\\ 0\\.1712058505866104\ \(0\)\
\-\ grade\\:\\ 0\\.171156595882202\ \(0\)\
\-\ bronchioloalveolar\\:\\ 0\\.16740209157087163\ \(0\)\
\-\ carcinoma\\:\\ 0\\.14237239217080555\ \(0\)\
\-\ suv\\:\\ 0\\.1412658051119799\ \(0\)\
\-\ low\\:\\ 0\\.13657676793481652\ \(0\)\
\-\ tumors\\:\\ 0\\.13128821130465945\ \(0\)\
\-\ activity\\:\\ 0\\.13106225818253858\ \(0\)\
\-\ carcinoid\\:\\ 0\\.1253653425160774\ \(0\)\
\-\ differentiated\\:\\ 0\\.11362399972081685\ \(0\)\
\-\ pulmonary\\:\\ 0\\.10881280613254839\ \(0\)\
\-\ metabolic\\:\\ 0\\.10788788649870266\ \(0\)\
\-\ glycolytic\\:\\ 0\\.09516117280306906\ \(0\)\
\-\ strategum\\:\\ 0\\.09516117280306906\ \(0\)\
\-\ c11\\:\\ 0\\.09516117280306906\ \(0\)\
\-\ isotopes\\:\\ 0\\.09516117280306906\ \(0\)\
\-\ cms\\:\\ 0\\.09516117280306906\ \(0\)\
\-\ nodule\\:\\ 0\\.09393445479940957\ \(0\)\
\-\ imaging\\:\\ 0\\.0938154012952162\ \(0\)\
\-\ tumor\\:\\ 0\\.09337343107134685\ \(0\)\
\-\ radiopharmaceuticals\\:\\ 0\\.09093158090056877\ \(0\)\
\-\ metastasis\\:\\ 0\\.08722528320665504\ \(0\)\
\-\ and\\:\\ 0\\.08607160806558856\ \(0\)\
\-\ avidity\\:\\ 0\\.0856029252933052\ \(0\)\
\-\ complicates\\:\\ 0\\.0856029252933052\ \(0\)\
\-\ acetate\\:\\ 0\\.0856029252933052\ \(0\)\
\-\ mucoepidermoid\\:\\ 0\\.08209302957362319\ \(0\)\
\-\ given\\:\\ 0\\.08186654751685707\ \(0\)\
\-\ of\\:\\ 0\\.08151381900505354\ \(0\)\
\-\ elevated\\:\\ 0\\.08113046605175661\ \(0\)\
\-\ experimental\\:\\ 0\\.08070010257280318\ \(0\)\
\-\ approved\\:\\ 0\\.08070010257280318\ \(0\)\
\-\ esophagectomy\\:\\ 0\\.07947145388293551\ \(0\)\
\-\ unexplained\\:\\ 0\\.07947145388293551\ \(0\)\
\-\ showed\\:\\ 0\\.07926884455526055\ \(0\)\
\-\ cancer\\:\\ 0\\.07926884455526055\ \(0\)\
\-\ opted\\:\\ 0\\.07837239017817225\ \(0\)\
\-\ such\\:\\ 0\\.07655307523011895\ \(0\)\
\-\ pleasant\\:\\ 0\\.07647051067030287\ \(0\)\
\-\ valuable\\:\\ 0\\.07647051067030287\ \(0\)\
\-\ routinely\\:\\ 0\\.07647051067030287\ \(0\)\
\-\ correlating\\:\\ 0\\.07486249445849025\ \(0\)\
\-\ examples\\:\\ 0\\.07414279827567194\ \(0\)\
\-\ alternatively\\:\\ 0\\.07414279827567194\ \(0\)\
\-\ irradiation\\:\\ 0\\.07346956745767022\ \(0\)\
\-\ bronchoalveolar\\:\\ 0\\.07346956745767022\ \(0\)\
\-\ adenoid\\:\\ 0\\.07283716431274036\ \(0\)\
\-\ aka\\:\\ 0\\.07283716431274036\ \(0\)\
\-\ include\\:\\ 0\\.07080966075025993\ \(0\)\
\-\ differentiating\\:\\ 0\\.07063290255598995\ \(0\)\
\-\ decreases\\:\\ 0\\.07063290255598995\ \(0\)\
\-\ performed\\:\\ 0\\.07040650010223469\ \(0\)\
\-\ beam\\:\\ 0\\.0696839343494523\ \(0\)\
\-\ significant\\:\\ 0\\.06871355268488936\ \(0\)\
\-\ cm\\:\\ 0\\.0683485944401003\ \(0\)\
\-\ one\\:\\ 0\\.06813861365940799\ \(0\)\
\-\ specificity\\:\\ 0\\.06801132686530227\ \(0\)\
\-\ largely\\:\\ 0\\.06801132686530227\ \(0\)\
\-\ ct\\:\\ 0\\.06796213909085477\ \(0\)\
\-\ borderline\\:\\ 0\\.06726590574428361\ \(0\)\
\-\ these\\:\\ 0\\.06720473291971711\ \(0\)\
\-\ 86\\:\\ 0\\.06623903234253728\ \(0\)\
\-\ functioning\\:\\ 0\\.06591803910361058\ \(0\)\
\-\ pounds\\:\\ 0\\.0656066291976074\ \(0\)\
\-\ is\\:\\ 0\\.06518320473184314\ \(0\)\
\-\ mucinous\\:\\ 0\\.06365374001766004\ \(0\)\
\-\ among\\:\\ 0\\.06291709589097794\ \(0\)\
\-\ without\\:\\ 0\\.06277311818713832\ \(0\)\
\-\ elderly\\:\\ 0\\.0626826712580387\ \(0\)\
\-\ increases\\:\\ 0\\.062453399234319355\ \(0\)\
\-\ can\\:\\ 0\\.0624524962894153\ \(0\)\
\-\ classically\\:\\ 0\\.06222905817602086\ \(0\)\
\-\ or\\:\\ 0\\.062102009368021634\ \(0\)\
\-\ demonstrate\\:\\ 0\\.06186982063893333\ \(0\)\
\-\ extremely\\:\\ 0\\.06097577793479453\ \(0\)\
\-\ lower\\:\\ 0\\.06081406333569604\ \(0\)\
\-\ pleomorphic\\:\\ 0\\.06021679184807554\ \(0\)\
\-\ glass\\:\\ 0\\.059857050779998464\ \(0\)\
\-\ the\\:\\ 0\\.05936684574061576\ \(0\)\
\-\ ground\\:\\ 0\\.05792574542143572\ \(0\)\
\-\ well\\:\\ 0\\.057625061251814554\ \(0\)\
\-\ female\\:\\ 0\\.0574276472563519\ \(0\)\
\-\ dependent\\:\\ 0\\.05735401565077512\ \(0\)\
\-\ workup\\:\\ 0\\.056048381687843526\ \(0\)\
\-\ advanced\\:\\ 0\\.05592637495018728\ \(0\)\
\-\ bacterial\\:\\ 0\\.05568656077584498\ \(0\)\
\-\ thus\\:\\ 0\\.0546708063559511\ \(0\)\
\-\ definitive\\:\\ 0\\.054353072438142476\ \(0\)\
\-\ options\\:\\ 0\\.05364729414551903\ \(0\)\
\-\ times\\:\\ 0\\.05355025663503637\ \(0\)\
\-\ unlikely\\:\\ 0\\.052715294559483684\ \(0\)\
\-\ still\\:\\ 0\\.052715294559483684\ \(0\)\
\-\ though\\:\\ 0\\.05169678304768698\ \(0\)\
\-\ lack\\:\\ 0\\.050917954509312476\ \(0\)\
\-\ esophageal\\:\\ 0\\.05084317671846047\ \(0\)\
\-\ factors\\:\\ 0\\.05033422421141111\ \(0\)\
\-\ point\\:\\ 0\\.04919266978739415\ \(0\)\
\-\ atypical\\:\\ 0\\.04881784657271058\ \(0\)\
\-\ be\\:\\ 0\\.04827745897800651\ \(0\)\
\-\ external\\:\\ 0\\.048106335135038404\ \(0\)\
\-\ compared\\:\\ 0\\.048106335135038404\ \(0\)\
\-\ as\\:\\ 0\\.047810401805784934\ \(0\)\
\-\ not\\:\\ 0\\.046982180550957785\ \(0\)\
\-\ many\\:\\ 0\\.0469159670648412\ \(0\)\
\-\ where\\:\\ 0\\.046763680314185804\ \(0\)\
\-\ delayed\\:\\ 0\\.0465640291068302\ \(0\)\
\-\ considered\\:\\ 0\\.0463681274404234\ \(0\)\
\-\ cells\\:\\ 0\\.04584762932383506\ \(0\)\
\-\ currently\\:\\ 0\\.045710069653683835\ \(0\)\
\-\ enhanced\\:\\ 0\\.04530795085302857\ \(0\)\
\-\ are\\:\\ 0\\.045158751256999696\ \(0\)\
\-\ rate\\:\\ 0\\.04509107283003577\ \(0\)\
\-\ note\\:\\ 0\\.0447948249283786\ \(0\)\
\-\ second\\:\\ 0\\.044547426997138435\ \(0\)\
\-\ used\\:\\ 0\\.044547426997138435\ \(0\)\
\-\ classic\\:\\ 0\\.044506758496685304\ \(0\)\
\-\ abnormalities\\:\\ 0\\.04310368909627816\ \(0\)\
\-\ above\\:\\ 0\\.04292777502600046\ \(0\)\
\-\ early\\:\\ 0\\.042892945420509226\ \(0\)\
\-\ malignant\\:\\ 0\\.04241716132663075\ \(0\)\
\-\ status\\:\\ 0\\.041526129715309335\ \(0\)\
\-\ weight\\:\\ 0\\.04149567288446553\ \(0\)\
\-\ left\\:\\ 0\\.04059678866211627\ \(0\)\
\-\ 30\\:\\ 0\\.04059308740064921\ \(0\)\
\-\ although\\:\\ 0\\.04050974642083177\ \(0\)\
\-\ available\\:\\ 0\\.04037230757953589\ \(0\)\
\-\ size\\:\\ 0\\.04029070515176818\ \(0\)\
\-\ initial\\:\\ 0\\.03991811350349671\ \(0\)\
\-\ several\\:\\ 0\\.03904100406897585\ \(0\)\
\-\ further\\:\\ 0\\.03875649214705821\ \(0\)\
\-\ past\\:\\ 0\\.03873312941130474\ \(0\)\
\-\ will\\:\\ 0\\.038298898732204295\ \(0\)\
\-\ resection\\:\\ 0\\.03814336826836203\ \(0\)\
\-\ age\\:\\ 0\\.03735771955507732\ \(0\)\
\-\ only\\:\\ 0\\.0371752404326828\ \(0\)\
\-\ year\\:\\ 0\\.03667643233673329\ \(0\)\
\-\ years\\:\\ 0\\.0364756627848443\ \(0\)\
\-\ evaluation\\:\\ 0\\.03628938181407119\ \(0\)\
\-\ loss\\:\\ 0\\.03625252150309018\ \(0\)\
\-\ lung\\:\\ 0\\.03619747410804577\ \(0\)\
\-\ for\\:\\ 0\\.03607091283899622\ \(0\)\
\-\ cystic\\:\\ 0\\.035837733039968685\ \(0\)\
\-\ abnormal\\:\\ 0\\.035749703343264695\ \(0\)\
\-\ lymphoma\\:\\ 0\\.03543880909297005\ \(0\)\
\-\ however\\:\\ 0\\.03521990042520882\ \(0\)\
\-\ with\\:\\ 0\\.034955367211065166\ \(0\)\
\-\ lobe\\:\\ 0\\.03438750230620181\ \(0\)\
\-\ lesions\\:\\ 0\\.03417429722005015\ \(0\)\
\-\ high\\:\\ 0\\.033818644915240934\ \(0\)\
\-\ evidence\\:\\ 0\\.033775029002972884\ \(0\)\
\-\ patients\\:\\ 0\\.03347471957221166\ \(0\)\
\-\ prior\\:\\ 0\\.03329305531191601\ \(0\)\
\-\ over\\:\\ 0\\.033087299979505186\ \(0\)\
\-\ more\\:\\ 0\\.03267451457055919\ \(0\)\
\-\ post\\:\\ 0\\.03237847556124947\ \(0\)\
\-\ physical\\:\\ 0\\.03226488325381524\ \(0\)\
\-\ increased\\:\\ 0\\.0321773810030799\ \(0\)\
\-\ chest\\:\\ 0\\.031409663105568905\ \(0\)\
\-\ most\\:\\ 0\\.03096811392464726\ \(0\)\
\-\ other\\:\\ 0\\.03090181206699146\ \(0\)\
\-\ were\\:\\ 0\\.030673018978886787\ \(0\)\
\-\ exam\\:\\ 0\\.02995475973486181\ \(0\)\
\-\ to\\:\\ 0\\.02975217978913665\ \(0\)\
\-\ in\\:\\ 0\\.0296057396218334\ \(0\)\
\-\ multiple\\:\\ 0\\.029105106008245053\ \(0\)\
\-\ presents\\:\\ 0\\.028624893361061443\ \(0\)\
\-\ lesion\\:\\ 0\\.028527937843741632\ \(0\)\
\-\ treatment\\:\\ 0\\.028345306584255863\ \(0\)\
\-\ seen\\:\\ 0\\.028014390809052304\ \(0\)\
\-\ which\\:\\ 0\\.027057436936546726\ \(0\)\
\-\ from\\:\\ 0\\.02363279458933551\ \(0\)\
\-\ history\\:\\ 0\\.022734288737396705\ \(0\)\
\-\ at\\:\\ 0\\.022475726514466065\ \(0\)\
\-\ patient\\:\\ 0\\.019353933052138762\ \(0\)\
\-\ no\\:\\ 0\\.019350292690156756\ \(0\)\
\-\ on\\:\\ 0\\.017971479174163363\ \(0\)\
\-\ old\\:\\ 0\\.017611035452692568\ \(0\)\
